IceCure files for Canadian regulatory clearance for ProSense

By staff writers

July 26, 2022 -- IceCure Medical has filed paperwork with Health Canada requesting clearance for market of its ProSense liquid nitrogen-based cryoablation system.

ProSense is used to ablate both benign and malignant breast, lung, liver, and musculoskeletal, lung, and renal lesions, as well as for palliative treatment. It currently has marketing clearance in the U.S. and Europe.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking